Inhibition of 5-lipoxygenase triggers apoptosis in prostate cancer cells via down-regulation of protein kinase C-epsilon

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 12, 2011, Pages 2108-2117

  Sarveswaran, Sivalokanathan ^a   Thamilselvan, Vijayalakshmi ^a   Brodie, Chaya ^b   Ghosh, Jagadananda ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

5 Lipoxygenase; Apoptosis; PKC epsilon; Prostate cancer

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; DIAZOXIDE; PHOSPHATIDYLSERINE; PROTEIN KINASE C EPSILON; QUIFLAPON;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL STRAIN LNCAP; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME INACTIVATION; ENZYME INHIBITION; FATTY ACID METABOLISM; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

APOPTOSIS; ARACHIDONATE 5-LIPOXYGENASE; BLOTTING, WESTERN; DOWN-REGULATION; EICOSANOIDS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; LIPOXYGENASE INHIBITORS; MALE; PROSTATIC NEOPLASMS; PROTEIN KINASE C-EPSILON; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 82555167048     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.07.015     Document Type: Article

References (53)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
2. Crawford E.D., Eisenberger M.A., McLeod D.G., Spaulding J.T., Benson R., Dorr F.A., Blumenstein B.A., Davis M.A., Goodman P.J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 1989, 321:419-424.
3. Fleshner N., Bagnell P.S., Klotz L., Venkateswaran V. Dietary fat and prostate cancer. J. Urol. 2004, 171:19-24.
4. Kolonel L.N., Nomura A.N., Cooney R.V. Dietary fat and prostate cancer: current status. J. Natl. Cancer Inst. 1999, 91:414-428.
5. West D.W., Slattery M.L., Robison L.M., French T.K., Mahoney A.W. Adult dietary intake and prostate cancer risk in Utah: a case control study with special emphasis on aggressive tumors. Cancer Causes Control 1991, 2:85-94.
6. Giovannucci E.L., Rimm E.B., Colditz G.A., Stampfer M.J., Ascherio A., Chute C., Willett W.C. A prospective study of dietary fat and risk of prostate cancer. J. Natl. Cancer Inst. 1993, 85:1571-1579.
7. Gann P.H., Hennekens C.H., Sacks F.M., Grodstein F., Giovannucci E.L., Stampfer M.J. Prospective study of plasma fatty acids and risk of prostate cancer. J. Natl. Cancer Inst. 1994, 86:281-286.
8. Wang Y., Corr J.G., Thaler H.T., Tao Y., Fair W.R., Heston W.D. Decreased growth of established prostate LNCaP tumors in nude mice fed a low-fat diet. J. Natl. Cancer Inst. 1995, 87:1456-1462.
9. Ghosh J., Myers C.E. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem. Biophys. Res. Commun. 1997, 235:418-423.
10. Ghosh J., Myers C.E. Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells. Adv. Exp. Med. Biol. 1999, 469:577-582.
11. Anderson K.M., Seed T., Vos M., Mulshine J., Meng J., Alrefai W., Ou D., Harris J.E. 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate nonnecrotic cell death. Prostate 1998, 37:161-173.
12. Ghosh J., Myers C.E. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:13182-13187.
13. Ghosh J. Inhibition of arachidonate 5-lipoxygenase triggers prostate cancer cell death through rapid activation of c-Jun N-terminal kinase. Biochem. Biophys. Res. Commun. 2003, 307:342-349.
14. Werz O., Steinhilber D. Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol. Ther. 2006, 112:701-718.
15. Radmark O., Werz O., Steinhilber D., Samuelsson B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem. Sci. 2007, 32:332-341.
16. Furstenberger G., Krieg P., Muller-Decker K., Habenicht A.J. What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis?. Int. J. Cancer 2006, 119:2247-2254.
17. Ghosh J. Targeting 5-lipoxygenase for prevention and treatment of cancer. Curr. Enzyme Inhib. 2008, 4:18-28.
18. Wang D., DuBois R.N. Eicosanoids and cancer. Nat. Rev. Cancer 2010, 10:181-193.
19. Gonzalez-Periz A., Claria J. New approaches to the modulation of the cyclooxygenase-2 and 5-lipoxygenase pathways. Curr. Top. Med. Chem. 2007, 7:297-309.
20. Gupta S., Srivastava M., Ahmad N., Sakamoto K., Bostwick D.G., Mukhtar H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 2001, 91:737-743.
21. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
22. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7:606-619.
23. Marte B.M., Downward J. PKB/Akt: connecting phosphoinositide3-kinase to cell survival and beyond. Trends Biochem. Sci. 1997, 22:355-358.
24. Altomare D.A., Testa J.R. Perturbations of the Akt signaling pathway in human cancer. Oncogene 2005, 24:7455-7464.
25. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4:988-1004.
26. Balmanno K., Cook S.J. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 2009, 16:368-377.
27. Boutros T., Chevet E., Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol. Rev. 2008, 60:261-310.
28. Mebratu Y., Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer?. Cell Cycle 2009, 8:1168-1175.
29. Sarveswaran S., Myers C.E., Ghosh J. MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase. Cancer Lett. 2010, 291:167-176.
30. Ferguson A.D., McKeever B.M., Xu S., Wisniewski D., Miller D.K., Yamin T.T., Spencer R.H., Chu L., Ujjainwalla F., Cunningham B.R., Evans J.F., Becker J.W. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 2007, 317:510-512.
31. Evans J.F., Ferguson A.D., Mosley R.T., Hutchinson J.H. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol. Sci. 2008, 29:72-78.
32. Basu A., Sivaprasad U. Protein kinase Cε makes the life and death decision. Cell. Signal. 2007, 19:1633-1642.
33. Sivaprasad U., Shankar E., Basu A. Downregulation of Bid is associated with PKCepsilon-mediated TRAIL resistance. Cell Death Differ. 2007, 14:851-860.
34. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 1995, 9:484-496.
35. Mellor H., Parker P.J. The extended protein kinase C superfamily. Biochem. J. 1998, 332:281-292.
36. Newton A.C. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem. Rev. 2001, 101:2353-2364.
37. Griner E.M., Kazanietz M.G. Protein kinase C and other diacylglycerol effectors in cancer. Nat. Rev. Cancer 2007, 7:281-294.
38. Gavrielides M.V., Frijhoff A.F., Conti C.J., Kazanietz M.G. Protein kinase C and prostate carcinogenesis: targeting the cell cycle and apoptotic mechanisms. Curr. Drug Targets 2004, 5:431-443.
39. McJilton M.A., Sikes C.V., Wescott G.G., Wu D., Foreman T.L., Gregory C.W., Weidner D.A., Ford O.H., Lasater A.M., Mohler J.L., Terrian D.M. Protein kinase Cε interacts with Bax and promotes survival of human prostate cancer cells. Oncogene 2003, 22:7958-7968.
40. Maddipati K.R., Zhou S.L. Stability and analysis of eicosanoids and docosanoids in tissue culture media. Prostaglandins Other Lipid Mediat. 2011, 94:59-72.
41. Horoszewicz J.S., Leong S.S., Chu T.M., Wajsman Z.L., Friedman M., Papsidero L., Kim U., Chai L.S., Kakati S., Arya S.K., Sandberg A.A. The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog. Clin. Biol. Res. 1980, 37:115-132.
42. Aziz M.H., Manoharan H.T., Church D.R., Dreckschmidt N.E., Zhong W., Oberley T.D., Wilding G., Verm A.K. Protein kinase C-ε interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3-Ser727, and regulates its constitutive activation in prostate cancer. Cancer Res. 2007, 67:8828-8838.
43. ATP channel conferring cardioprotection against hypoxic injury. Br. J. Pharmacol. 2006, 149:1059-1070.
44. Dorn G.W., Souroujon M.C., Liron T., Chen C.H., Gray M.O., Zhou H.Z., Csukai M., Wu G., Lorenz J.N., Mochly-Rosen D. Sustained in vivo cardiac protection by a rationally designed peptide that causes ε protein kinase C translocation. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:12798-12803.
45. Carson J.P., Kulik G., Weber M.J. Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3'-kinase and Akt/Protein Kinase B. Cancer Res. 1999, 59:1449-1453.
46. Sundaram S., Ghosh J. Expression of 5-oxoETE receptor in prostate cancer cells: critical role in survival. Biochem. Biophys. Res. Commun. 2006, 339:93-98.
47. Hosoi T., Koguchi Y., Sugikawa E., Chikada A., Ogawa K., Tsuda N., Suto N., Tsunoda S., Taniguchi T., Ohnuki T. Identification of a novel human eicosanoid receptor coupled to G(i/o). J. Biol. Chem. 2002, 277:31459-31465.
48. Jones C.E., Holden S., Tenaillon L., Bhatia U., Seuwen K., Tranter P., Turner J., Kettle R., Bouhelal R., Charlton S., Nirmala N.R., Jarai G., Finan P. Expression and characterization of a 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid receptor highly expressed on human eosinophils and neutrophils. Mol. Pharmacol. 2003, 63:471-477.
49. Felber M., Sonnemann J., Beck J.F. Inhibition of novel protein kinase C-epsilon augments TRAIL-induced cell death in A549 lung cancer cells. Pathol. Oncol. Res. 2007, 13:295-301.
50. Flescher E., Rotem R. Protein kinase Cε mediates the induction of P-glycoprotein in LNCaP prostate carcinoma cells. Cell. Signal. 2002, 14:37-43.
51. Gorin M.A., Pan Q. Protein kinase Cε: an oncogene and emerging tumor biomarker. Mol. Cancer 2009, 8:9.
52. Wu D., Foreman T.L., Gregory C.W. Protein kinase Cε has the potential to advance the recurrence of human prostate cancer. Cancer Res. 2002, 62:2423-2429.
53. Hafeez B.B., Zhong W., Weichert J., Dreckschmidt N.E., Jamal M.S., Verma A.K. Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma. Cancer Res. 2011, 71:2318-2327.